The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000

Turner, Philip; Greenhalgh, J.M.; KURT, HATİCE; Eraksoy, H.; Ozturk, R.; Basustaoglu, A.; Korten, V.; Unal, S.; Ulusoy, S.; Yuce, A.; Taoova, Y.; Verhaegen, J.; Verschraegen, G.; de Mol, P.; Glupczynski, G.; Delmee, M.; Lauwers, S.; Struelens, M.; Masterton, R.; Hood, J.; Bint, A.; Chadwick, P.; Holliman, R.; Riley, U.; Swann, R.A.; Priztbuer, E.; Thomssen, R.; Rodloff, A.; Heesemann, J.; Hahn, H.; Schaal, K.-P.; Giacobone, E.; Fontana, R.; Markova, B.; Chemelerova, E.; Dzierzanowska, D.; Resvan, S.V.; Larsson, P.; Bille, J.

doi:10.1046/j.1469-0691.2003.00591.x

The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000

Turner P. J., Greenhalgh J., KURT H., Eraksoy H., Ozturk R., Basustaoglu A., ...Daha Fazla

Clinical Microbiology and Infection, cilt.9, sa.6, ss.563-567, 2003 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 9 Sayı: 6
Basım Tarihi: 2003
Doi Numarası: 10.1046/j.1469-0691.2003.00591.x
Dergi Adı: Clinical Microbiology and Infection
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.563-567
Anahtar Kelimeler: Acinetobacter, Antibiotics, Carbapenems, Meropenem, MYSTIC
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Evet

Özet

In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.